DBVT News and Press, DBV Technologies S.A. From 05/19/25

2025-05-19 16:23:48 ET More on DBV Technologies DBV Technologies: A Great Time To Sell DBV Technologies announces up to $307M financing to advance Viaskin Peanut program Read the full article on Seeking Alpha For further details see: DBV Technologies file...

Châtillon, France, May 15, 2025 Combined General Meeting of June 11, 2025 Procedures for Obtaining Information and Preparatory Documents for the Combined General Meeting DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a cli...

2025-05-13 14:44:55 ET Summary DBV Technologies focuses on the Viaskin Peanut Patch for childhood peanut allergies. The company faced setbacks, including FDA denial and competition, leading to significant financial losses and stock price drops. A new round of financing on favo...

Information regarding the total number of voting rights and total number of shares of the Company as of April 30, 2025 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers ) Market : NYSE Euronext Paris ISIN Code: FR 0010417345 ...

Cyclerion Therapeutics Inc. (CYCN) is expected to report for Q1 2025 Standard BioTools Inc. (LAB) is expected to report $-0.06 for Q1 2025 Christian Dior SE ADR (CHDRY) is expected to report for Q1 2025 CF Bankshares Inc. (CFBK) is expected to report for Q1 2025 Jack Henry & A...

Châtillon, France, May 5, 2025 DBV Technologies to Participate in the Citizens JMP Life Sciences Conference DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced Daniel Tass...

2025-04-30 17:38:37 ET More on DBV Technologies DBV Technologies announces up to $307M financing to advance Viaskin Peanut program Seeking Alpha’s Quant Rating on DBV Technologies Historical earnings data for DBV Technologies Financial information for ...

Châtillon, France, April 30, 2025 DBV Technologies Reports First Quarter 2025 Financial Results DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP: 23306J309), a clinical-stage biopharmaceutical company, today reported fi...

Châtillon, France, April 11, 2025 DBV Technologies announces filing of 2024 Annual Report on Form 10-K and Universal Registration Document DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company f...

2025-04-08 16:10:00 ET Today's pharmaceutical stocks are facing the challenges of government-imposed drug price caps, waning demand for COVID-19 vaccines and global stock market upheaval. However, the industry's major underlying drivers — higher rates of cancer and chronic di...